Who is eligible for clinical trial NCT05071937?

Participants must meet the protocol's inclusion criteria for Ovarian Cancer. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05071937 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer (NCT05071937)

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Alexander B Olawaiye, MD

🩺 Plain-English Summary (8th-Grade Level)

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (22 items) and avoid the listed exclusions (25 items).

Location: University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania

Age range: 18 Years

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Current or anticipated use of medications known to be strong inhibitors or inducers of CYP3A4 or substrates of CYP1A2 with narrow therapeutic windows. Strong inhibitors, inducers or substrates must be discontinued at least 7 days prior to the first administration of study drug.
Current or anticipated use within 7 days prior to the first administration of study drug, or during the study, of strong P-gp inhibitors.
Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed
Radiation to \>25% of the bone marrow
Treatment with a bone-targeted radionuclide within 6 weeks of first dose of study drug
Prior chemotherapy or radiation within 3 weeks of study enrollment
Have previously received an investigational BET inhibitor (including previous participation in studies with Zenith drug, ZEN003694)
QTcF interval \> 470 msec
Insufficient recovery from prior treatment-related toxicities except for alopecia, fatigue and Grade 2 neuropathy
Non-healing wound, ulcer or bone fracture (not including a pathological bone fracture caused by a pre-existing pathological bone lesion)
Brain metastases not adequately treated and/or clinically stable (at the discretion of the Investigator) for at least 6 months prior to the start of study treatment.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania

📞 Contact the Study Coordinator

Phone: (412) 648-6417

Email: adamikka2@upmc.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗